Ann: 2023 Results webinar, page-51

My overall impression from the web conference was that everyone looked very tired – I got the impression that everyone has been working their butts off.
Two comments by Jon stood out to me (approx. 42-45m timestamp).
Firstly, there was a reference to many things going on in the company at the moment within the context of exploration of options going forward.

The other formed part of the response to a question on whether the Company might provide guidance on anticipated R & D costs. In short, the answer was not at this time as there are still too many unknown factors involved, but it was Jon’s comment that one of the unknown factors was “how much we’re going to fund ourselves” that struck me.

I’m now tending toward the thinking that Neuren will choose to partner with a specialist life sciences funding firm, such as Carlyle Abingworth’s Launch Therapeutics or Blackstone Life Sciences to accelerate current pipeline development as well as add further programs to the pipeline. These type of firms specialise in bringing both substantial capital and clinical trial and regulatory expertise to the table for life science companies with late stage assets. Arrangements are flexible. While there is obviously a significant cost, under such an arrangement, Neuren could continue to retain full rights and control of its assets, thus leaving more future options open.

https://www.blackstone.com/our-businesses/life-sciences/
https://www.carlyle.com/media-room/...es-356-million-new-clinical-co-development-co
https://www.fiercebiotech.com/biotech/abingworth-closes-356m-fund-late-stage-biopharma-programs
https://launchtx.com/
https://www.abingworth.com/media/ab...tween-launch-therapeutics-and-gilead-sciences